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Ltd. This is an open access article unAbstract Interleukin-6 (IL-6) is a pleiotropic cytokine which plays an important role in a num-
ber of cellular processes including proliferation, survival, differentiation, migration and inva-
sion. IL-6 mediates its downstream effects by activating a number of signaling cascades
including JAK/STAT, PI3K/AKT and MAPK pathways. In addition to its effects on tumor cells,
IL-6 also regulates tumor progression and tumor metastasis by modulating tumor angiogenesis
and tumor lymphangiogenesis. A number of studies have shown that IL-6 levels are markedly
upregulated in cancer patients. We and others have shown that high IL-6 expression indepen-
dently predicts tumor recurrence, tumor metastasis and poor survival in head and neck cancer
patients. Therefore targeting IL-6 signaling is a potential therapeutic strategy for the treat-
ment of head and neck squamous cell carcinoma (HNSCC). In this review, we discuss the cur-
rent understanding of the role of IL-6 in HNSCC progression and potential therapeutic
strategies to target IL-6 signaling for the treatment of head and neck cancer patients.
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Role of IL-6 in HNSCC 91Introduction
Head and neck squamous cell carcinoma (HNSCC) remains a
major health care problem worldwide, comprising almost
50% of all malignancies in some developing nations.1e3
Although advancements in the anti-cancer treatments
including surgery, radiation and chemotherapy have
increased the local control of HNSCC, the overall survival
rates have not improved significantly over the last three
decades.3,4 Five year survival rates for patients with early
stage localized head and neck cancers are more than 80%
but drops to 40% when the disease has spread to the neck
nodes, and to below 20% for patients with distant meta-
static disease.4 Acquisition of chemoresistance and meta-
static phenotype are the major causes of treatment failure
and mortality in these patients.1,5 It is therefore imperative
that we gain a better understanding of the molecular
mechanisms that contribute to the aggressive tumor
phenotype in order to develop novel and effective strate-
gies for the treatment of head and neck cancer patients.
Interleukin-6 (IL-6) is one of the key molecules that has
been widely studied and implicated in poor clinical out-
comes in HNSCC patients.6e10 IL-6 was initially identified
and cloned as B-cell stimulatory factor-2.11e13 At the same
time a number of other molecules (IFN-b2, plasmacytoma
growth factor and hepatocyte-stimulating factor) were
independently cloned and found to be identical to IL-
6.14e16 Accumulating evidence has shown that IL-6 plays an
important role in a number of biological process including
immune regulation, hematopoiesis, inflammation and
oncogenesis.17e19 IL-6 is produced by a wide variety of cell
types including immune cells (macrophages, dendritic cells
and B-cells), endothelial cells and tumor cells.20e23 We and
others have shown that IL-6 levels are markedly elevated in
the blood samples from cancer patients including HNSCC
and independently predict tumor recurrence, poor survival
and tumor metastasis.6e8 A number of mechanistic studies
have corroborated these clinical observations. Using our
in vitro and in vivo head and neck cancer models, we were
able to demonstrate that IL-6 is a potent inducer of
epithelial to mesenchymal transition (EMT) in head and
neck cancer cell lines thereby promoting regional (lymph
node) and distant (lung) metastasis.20 Similarly, Lederle
et al24 demonstrated that IL-6 promotes malignant growth
of squamous cell carcinoma by regulating a complex cyto-
kine and protease network. Recent studies have also high-
lighted the role of IL-6 in the acquisition of
chemoresistance and stem cell phenotype in cancer
cells.25e28 We hereby present a review of recent studies
that demonstrate the role of IL-6 in head and neck cancer
progression.
Clinical significance of IL-6 in HNSCC
The association of IL-6 with clinical parameters (clinico-
pathological factors) and oncological outcomes in HNSCC
has been largely studied over the past two decades. Several
studies have shown elevated levels of IL-6 in HNSCC.6,8,26,29
In a study of 65 untreated HNSCC patients and 20 healthy
volunteers, Mojtahedi et al29 found that serum levels of IL-6
and IL-18 were significantly increased in HNSCC patientscompared to healthy individuals, however only the differ-
ence of IL-6 levels was found to be statistically significant.
In addition, they showed that IL-6 concentration increased
as tumor stage progressed and a significant difference was
observed between stage IV vs stage I/II/III disease. These
results suggest the activation of the Th2 arm of the immune
response in HNSCC patients. However, Lathers et al30 found
elevated levels of IL-2 and GM-CSF in addition to IL-4, IL-6
and IL-10, thereby suggesting that HNSCC patients might
have incomplete Th2 skewing. This theory of incomplete
Th2 immune switch was further supported by the work of
Sparano et al31 where they examined blood samples from 58
patients of histologically proven HNSCC and showed that
there were significantly higher levels of IL-6 and IL-10 as
compared to IL-12. In addition, they showed that T3 and T4
patients had a positive relationship between tumor size and
serum IL-6 levels. Similarly, in a caseecontrol study of 90
HNSCC patients and 39 controls, Riedel et al8 showed higher
levels of IL-6 in serum of HNSCC compared to healthy
controls. They also showed a statistically significant cor-
relation between serum IL-6 concentrations and with higher
tumor stage and positive lymph nodes. In a prospective
study of 85 patients with primary HNSCC, Tartour et al32
showed a significant association between higher lymph
node (N) classification and elevated serum IL-6 levels.
In addition to serum levels of IL-6, tumor IL-6 expression
both at mRNA and protein levels are also directly correlated
with higher tumor stage and positive lymph nodes.9,33 Wang
et al33 examined IL-6R and IL-6 mRNA expression in 86 oral
squamous cell carcinoma tumor specimens and showed
significantly higher IL-6R and IL-6 mRNA expression in tumor
samples as compared to normal mucosa. IL-6 and IL-6R
mRNA levels were also associated with larger tumors and
more advanced histological grade. We have recently
examined IL-6 expression in HNSCC by immunohistochem-
istry and our results show a direct correlation between IL-6
expression and tumor stage, tumor recurrence, perineural
invasion, extracapsular spread and inversely associated
with HPV status.9
Considering the direct correlation between elevated IL-6
levels and high risk clinicopathological features in HNSCC, it
does not come as a surprise that increased IL-6 levels are
also associated with poor oncological outcomes in HNSCC
and are reflective of a high burden of disease. This concept
is further strengthened by the reduction of IL-6 levels after
treatment in HNSCC patients. Several reports have studied
IL-6’s association with oncological outcomes in HNSCC.
Allen et al34 studied numerous cytokines (IL-6, IL-8, growth-
related oncogene-1 [GRO-1], VEGF and hepatocyte growth
factors) longitudinally in a small prospective study of 30
patients with advanced oropharyngeal HNSCC receiving
chemoradiation treatment by measuring serum levels at
baseline and every 3 months. They showed a significant
decrease in disease specific survival with longitudinal in-
crease in levels of IL-6, suggesting that IL-6 could be a
biomarker of treatment response and survival. Similarly, De
Schutter et al35 did a retrospective study of 34 patient
samples showing that pre-treatment IL-6 serum level is an
independent predictor of local control, disease free sur-
vival and overall survival. These concepts where further
strengthened by our large prospective, longitudinal cohort
study of 444 patients, where we have shown that serum IL-6
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prognosis.
Elevated IL-6 levels are not only linked to tumor pro-
gression but have also shown to mediate chemo and radio-
resistance in HNSCC. Jinno et al26 have shown that the high
IL-6 expressing group showed significantly poor tumor
response to the preoperative chemoradiotherapy as
compared to the negative or low IL-6 expressing group.
Similarly, Argiris et al36 showed that IL-6 levels were
inversely associated with tumor response to induction
chemotherapy in HNSCC patients with stages IIIeIVB
receiving cisplatin doclataxel and Cetuximab. Recently,
Stanam et al37 showed that upregulated IL-6 expression
contributes to erlotinib resistance in HNSCC. Additionally,
De Schutter et al35 report a potential link between IL-6 and
radio-resistance in HNSCC. High IL-6 levels in HNSCC pa-
tients have also been found to be associated with health
behaviors. We have recently shown that smoking (current
and former) and decreased sleep was directly correlated
with higher IL-6 levels.38 We also showed that smoking was
negatively associated with response to treatment and was
an independent predictor of recurrence and poor prognosis.
In addition, higher IL-6 levels were associated with muco-
sitis and weight loss in HNSCC patients.IL-6 effects on head and neck cancer
progression and metastasis
IL-6 is one of the cytokines that is commonly overexpressed
in most cancer types including HNSCC.6,7,39e43 IL-6 is a part
of the cytokine family that shares a common glycoprotein
130 receptor (gp130; also known as CD130).44,45 Other
members of IL-6 family include IL-11, leukemia inhibitory
factor (LIF), ciliar neurotrophic factor (CTNF), oncostatin M
(OSM), cardiotrophin-1 (CT-1) and cardiotrophin like cyto-
kine (CLC).46,47 IL-6 mediates its signaling by binding to an
80 kDa type-1 cell surface cytokine a-receptor subunit (IL-
6R; also known as CD126)48 and a universally expressed
130 kDa gp130 to form an IL-6/IL-6R/gp130 complex that is
clustered into a dimer structure (Fig. 1).49 Once IL-6/IL-6R/
gp130 complex is formed, it recruits multiple signaling
partners to mediate the IL-6’s wide range of cellular func-
tions. One of the widely studied IL-6-mediated signaling
pathway is the Jak family and STAT family of transcription
factors.46 Dimerization of IL-6/IL-6R/gp130 leads to the
activation of Jak family of kinases (Jak1, Jak2 and Tyk2)
and recruitment of STAT proteins (STAT1, STAT3 and
STAT5).50 STAT3 is one main STAT family member that is
extensively studied in cancer.51 Once STAT3 is activated, it
forms a dimer in which the SH2 domain of one phospho-
STAT3 binds to the phosphorylated Tyr705 of another
STAT3 molecule and vice versa.52 The STAT3 dimers then
translocate to the nucleus to regulate the expression a
number of genes. The activation of JAK/STAT3 signaling by
IL-6 is tightly regulated by SOCS (suppressor of cytokine
signaling) and PIAS (protein inhibitor of activated STAT).53
In addition to the activation of JAK/STAT3 pathway, IL-6
also mediates its signaling by activating PI3K/AKT, RAS/
MAPK and Wnt signaling pathways.20,54,55
Although gp130 is universally expressed in human cells, IL-
6R (gp126) expression is highly restricted to a few types ofcells.56 Recent studies have shown that IL-6 is still able to
mediate its signaling in the cells that lack IL-6R expression
through an alternate signaling mechanism known as ‘trans-
signaling’.57,58 In the ‘classical signaling’ pathway, IL-6 binds
to membrane-bound IL-6R, whereas in ‘trans-signaling’
circulating IL-6 binds to the soluble form of IL-6R (sIL-6R) and
then this complex binds to membrane-bound gp130 and
mediates the downstream signaling (Fig. 1). The significance
of trans-signaling was highlighted by the presence of the
biologically active form of sIL-6R in the blood samples from
cancer patients.59,60 The importance of the sIL-6R is high-
lighted by the finding that 70% of the sIL-6R forms complexes
with IL-6 in the blood and then binds directly to the
membrane-bound gp130.61 In addition, sIL-6R can function as
a carrier protein for IL-6, thereby markedly prolonging the
plasma half-life and signaling of IL-6.62
A number of studies have shown that IL-6 mediates
persistent activation of the STAT3 pathway and up regula-
tion of downstream target genes in head and neck cancers
leading to increased tumor cell proliferation, migration,
survival, invasion, epithelial to mesenchymal transition
(EMT), cancer stem cell expansion, and chemo-
resistance.20,37,63 In addition to IL-6, STAT3 can also be
activated by EGFR that is often overexpressed in head and
neck cancer cells.64 However, recent studies have shown
that the persistent activation of STAT3 in HNSCC is pre-
dominantly mediated by IL-6 and not by the EGFR
pathway.65,66 Sriuranpong et al65 examined the interplay
between STAT3, IL-6 and EGFR pathways using a panel of
HNSCC cell lines. They showed that STAT3 was active in
most of the cell lines, although only 3 out 10 HNSCC cell
lines were moderately to strongly positive for activated
EGFR. Even in EGFR-positive cell lines, STAT3 activation
was not dependent on EGFR activation, as activated STAT3
persisted after treatment with AG1478 (EGFR inhibitor). In
contrast, immunodepletion of IL-6 or blocking of gp130 (the
signaling unit of the IL-6R complex) abolished STAT3 phos-
phorylation, thereby confirming IL-6-dependent and EGFR-
independent STAT3 activation. In a similar study, Squarize
et al66 showed an increased activity of IL-6 promoter in
HNSCC cells, which was dependent on the presence of an
intact NFkappaB site. Higher IL-6 expression in turn pro-
moted STAT3 activation in the EGFR-independent manner.
The IL-6/STAT3 pathway has also been shown to promote
cell survival in HNSCC cells by modulating the expression of
serpin B3/B4, known as squamous cell carcinomas antigens
1 and 2.67 A study by Ahmed et al67 showed that targeting of
IL-6/STAT3 signaling by a novel antibody against gp130
significantly inhibited STAT3 activation leading to prompt
disappearance of cysteine proteases of serpin B3/B4 mRNAs
and markedly enhancing tumor cell apoptosis. Recent
studies have also shown that IL-6 modulates HNSCC
tumorigenesis through epigenetic gene silencing via
altering the CpG promoter methylation and repressing a
number of tumor suppressor genes including CHFR, GATA5
and PAX6.68
Epithelial-mesenchymal transition (EMT) is a key process
in tumor metastatic cascade that is characterized by the
loss of cellecell junctions and cell polarity, resulting in the
acquisition of migratory and invasive properties.69e71 We
have recently shown that IL-6 promotes EMT in head and
neck cancer cells by repressing E-cadherin expression via
Fig. 1 IL-6 signaling pathways. IL-6 can mediate its intracellular signal by using both membrane-bound IL-6 receptor (IL-6
classical signaling) or soluble IL-6 receptor (IL-6 trans-signaling). In the classical IL-6 signaling, IL-6 binds to membrane-bound IL-6R
(non-signaling receptor) and gp130 (signaling arm of IL-6 receptor) to form a complex. A complete functional complex consists of
dimers of IL-6, IL-6R and gp130. IL-6 trans-signaling occurs in cells that lacks IL-6R. In this pathway, IL-6 first binds to soluble IL-6R
(sIL-6R) to form a complex and then this complex binds to gp130 at the cell surface to mediate the intracellular signaling. A soluble
form of IL-6 is released from cell surfaces by proteolytic cleavage (ADAM 17) or splicing of IL-6R mRNA. In both types of signaling,
JAKs binds to Box1 and 2 of gp130 which leads to activation of JAKs. STATs also binds to gp130 but are phosphorylated by JAKs. IL-6
also activate PI3K/Akt pathway via JAKs. Both SOCS and SHP2 bind to gp130 via tyrosine 759. SOCS negatively regulate IL-6/STAT3
signaling by inhibiting both JAKs and STATs. SHP2 plays an important role in relating IL-6-mediated MAPK signaling.
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tumor cells or normal keratinocytes significantly decreased
IL-6-mediated cell scattering, cell motility and reversal of
EMT phenotype. Furthermore, tumor cells overexpressing
IL-6 showed marked increase in lymph node and lung
metastasis in a SCID mouse xenograft model. IL-6 has also
been shown to modulate tumor cell motility by a number of
downstream mediators. In our study, we show that IL-6/
STAT3 signaling modulate cell motility by regulating Focal
Adhesion Kinase (FAK) activation.20 Whereas Su et al63 have
shown that IL-6 enhances head and neck tumor cell motility
by stabilizing Twist via the activation of casein kinase 2.
Similarly, IL-6 has been shown to enhance head and neck
cancer cell invasiveness by enhancing the expressions of
MMP-1 and MMP-9.72e74 In addition, IL-6 also promotes
tumor growth, metastasis and chemoresistance by
enhancing tumor stem cell phenotype.25,28 We have
recently shown that RhoC modulates cancer stem cell
phenotype in head and neck cancer cells by regulating the
expression of key stem cell transcription factors (nanog,
oct3/4 and sox2) via the IL-6/STAT3 signaling pathway.25 IL-
6/STAT3 signaling cascade was also shown to enhance
cancer stem cell survival in HNSCC.28 Blocking of IL-6
signaling by tocilizumab (humanized anti-IL-6R antibody)
significantly decreased cancer stem cell population andmarkedly enhanced the anti-tumor effects of conventional
chemotherapy.75IL-6/STAT3 signaling as a potential target to
treat HNSCC patients
A number of clinical studies have shown that IL-6 levels are
directly associated with poor overall survival, higher tumor
stage, tumor recurrence and metastasis in a number of
cancer types including HNSCC.6e8,26,36,72 Therefore, tar-
geting IL-6 signaling is a potential therapeutic strategy for
the treatment of patients with HNSCC. Because IL-6 has
been shown to use multiple downstream molecules to
mediate its biological function, it comes as no surprise that
molecules with diverse modes of action have been tried as
therapeutics to block IL-6 signaling (Table 1). Johnson
et al76 employed high-content imaging (HCS) assays to
screen 1726 compounds from the Library of Pharmacolog-
ically Active Compounds and identified 51 inhibitors of IL-
6-induced pSTAT3 activation. However, only three of these
inhibitors selectively inhibited STAT3 as compared with
STAT1. They subsequently confirmed Azelastine, an H1
receptor antagonist, as a selective inhibitor of IL-6-
induced pSTAT3 activation that also reduced the growth
Table 1 Drugs designed to target IL-6 signaling.
Drug Activity
Ruxolitinib Inhibitor of JAK1 and JAK287
AZD1480 Inhibitor of JAK1 and JAK288
BMS-911543 Selective JAK2 inhibitor89
STAT3 decoy Highly specific inhibitor
of STAT385,86
Tocilizumab Humanized anti-human
IL-6R antibody28
Siltuximab Anti-IL-6 antibody91,92
G-quartet
Oligodeoxynucleotides
Disrupts STAT3
DNA binding96
mAb 1339 Anti-IL-6 monoclonal antibody97
BE-8 Anti-IL-6 monoclonal antibody90
Eriocalyxin B (EB) Inhibits constitutive
and IL-6-mediated
STAT3 activation98
Curcumin
(diferuloylmethane)
Curcumin analog
(H-4073)
Inhibits STAT3
phosphorylation and
nuclear translocation80
Inhibits STAT3 phosphorylation
and chemoresistance81
Azelastine Inhibits IL-6-mediated
STAT3 activation76
Guanidinoquinazolines,
Triazolothiadiazines,
Amino alcohols,
and Oxazole-piperazine
singleton
Inhibits IL-6-mediated
STAT3 activation77
94 M.M. Choudhary et al.of HNSCC cell lines. In the subsequent study, the same
group screened a library of 94,491 compounds from the
Molecular Library Screening Center Network (MLSCN) for
the ability to inhibit IL-6-induced pSTAT3 activation.77 Two
hundred and three concentration-dependent inhibitors of
IL-6-induced pSTAT3 activation were identified from this
library and finally four chemical series (Guanidinoquina-
zolines, Triazolothiadiazines, Amino alcohols, and
Oxazole-piperazine singleton) progressed to lead optimi-
zation stage.
Recent studies have demonstrated that curcumin, the
constituent of the spice turmeric, in addition to its anti-
inflammatory function also show potent anti-proliferative
property in several tumor types. Curcumin has been
shown to mediate its anti-tumor effects by inhibiting a
number of signaling pathways including IL-6/STAT3
pathway.78,79 However, use of curcumin has been
limited due to its poor bio-absorption.80 In order to
overcome the poor bio-absorption of curcumin, we have
recently developed a novel class of curcumin analogs,
based on diarylidenylpiperidones (DAP), by incorporating
a piperidone link to the beta-diketone structure and flu-
oro substitutions on the phenyl groups.81 This compound
(H-4073) showed >5 fold higher cellular uptake in head
and neck cancer cell lines as compared to curcumin and
inhibited cell proliferation in a dose dependent manner.
H-4073 mediated its anti-tumor effects by inhibiting JAK/
STAT3, FAK, Akt and VEGF signaling pathways that play
important roles in cell proliferation, migration, survival
and angiogenesis. In addition, pre-treatment of cisplatin-
resistant HNSCC cell lines with H-4073 significantly
reversed chemoresistance. In the SCID mouse xenograft
model, H-4073 significantly enhanced the anti-tumor and
anti-angiogenesis effects of cisplatin, with no added
systemic toxicity. Another plant based natural compound
()-epigallocatechingallate (EGCG) has been shown to
inhibit IL-6-mediated STAT3 phosphorylation.82e84 Lin
et al82 showed that EGCG induces Fas/CD95-mediated
apoptosis in head and neck squamous cell carcinoma
cells by inhibiting constitutive and IL-6-induced JAK/
STAT3 signaling. EGCG was also able to block EGFR
signaling and enhanced the anti-tumor effects of 5-
flurouracil based chemotherapy.83 Recently, a chemi-
cally modified cyclic STAT3 decoy oligonucleotide with
improved serum and thermal stability was designed and
tested in a nude mouse model. STAT3 decoy demon-
strated a significant decrease in tumor volume compared
with the control groups (mutant cyclic STAT3 decoy or
saline) in conjunction with down modulation of STAT3
target gene expression without any significant side ef-
fects.85 This STAT3 decoy oligonucleotide was further
tested in phase 0 clinical trials.86 Intravenous injection of
the cyclic STAT3 decoy inhibited tumor growth and
downregulated STAT3 target genes in the tumors.
Although targeting of the IL-6/STAT3 pathway in the
head and neck cancer seems very promising, it has been
challenging so far to target STAT3 using small molecule
inhibitors in humans. What appears more promising is the
use of JAK receptor antagonists. IL-6 phosphorylates STAT3
through Janus kinases (JAK) 1 & 2. Ruxolitinib is the first
FDA approved drug that targets JAK1 and JAK2 kinases for
myelofibrosis.87 Other drugs including AZD1480, apreclinical JAK1/2 inhibitor, suppressed IL-6-induced STAT3
phosphorylation and showed subsequent human tumor
growth suppression.88 Additionally, BMS-911543, a JAK2
selective inhibitor, showed similar suppression of tumor
growth.89 These drugs have not been tested in HNSCC yet.
However, their potential benefits by blocking IL-6/STAT3
signaling do warrant HNSCC studies.
Another strategy to target IL-6/STAT3 signaling is to
block IL-6 binding to IL-6R through neutralizing antibodies.
Antibodies targeting IL-6 prevent the association of the
ligand with its receptor, leading to prevention of STAT3
activation. Most of the studies using anti-IL-6 antibodies so
far have been carried out using murine or humanized
monoclonal antibodies.90e92 BE-8, a murine anti-IL-6
antibody, was developed by Diaclone and showed limited
anti-tumor response.90 It was shown that BE-8 could not
block the daily IL-6 production >8 mg.90 In addition BE-8
had a short half-life (3e4 days) and there is a natural
drawback of murine antibodies inducing host anti-mouse
antibody response.93 In contrast Siltuximab is a chimeric
humanized monoclonal antibody that was developed by
Centocor and has a much longer half-life (2 weeks).94
Siltuximab is currently in a phase II clinical trials for
treatment in prostate cancer and multiple myeloma.91,95
Recently, tocilizumab, a humanized anti-IL-6R antibody
(developed by Hoffmann-La Roche and Chugai), was tested
in head and neck cancer model and was shown to disrupt
primary human tumor initiation mediated by cancer stem
cells.28
Role of IL-6 in HNSCC 95Concluding remarks
In this review, we examined the role of IL-6 as a prognostic
marker for patients with HNSCC, the importance of IL-6 in
HNSCC tumor proliferation and metastasis, and finally the
therapeutic potential of targeting the IL-6/STAT3 pathway.
There is extensive data available to associate IL-6 levels in
patients with clinicopathological parameters and oncolog-
ical outcomes in HNSCC. Although IL-6 receptor is not
expressed universally in different cell types, IL-6 can still
mediate its intracellular signaling in these cells through
trans-signaling mechanisms. As a result, IL-6/STAT3
signaling pathway is examined as an important therapeu-
tic target. There has been extensive progress made in
designing and testing novel drugs that target IL-6 signaling
(Table 1), but we still need continued efforts to develop
novel drugs which could effectively block this signaling
pathway without significant adverse effects.Funding program
NIH/NCI-CA178649 (P. Kumar) and The Ohio State University
Comprehensive Cancer Center.References
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